Monte Rosa Therapeutics, Inc. - GLUE

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
Jul 08, 2026 SCHEDULE 13G/A T. Rowe Price Associates, Inc. 10.5% 8,861,282 View
Jul 06, 2026 SCHEDULE 13D/A — 5.0% — View
May 15, 2026 SCHEDULE 13G/A TCG Crossover GP II, LLC 2.7% 2,311,076 View
May 15, 2026 SCHEDULE 13G/A TCG Crossover Fund II, L.P. 2.7% 2,311,076 View
May 15, 2026 SCHEDULE 13G/A TCG Crossover GP III, LLC 2.7% 2,311,075 View
May 15, 2026 SCHEDULE 13G/A TCG Crossover Fund III, L.P. 2.7% 2,311,075 View
May 15, 2026 SCHEDULE 13G/A Chen Yu 5.5% 4,622,151 View
May 15, 2026 SCHEDULE 13G/A Baker Bros. Advisors LP 9.99% 8,876,346 View
May 15, 2026 SCHEDULE 13G/A Baker Bros. Advisors (GP) LLC 9.99% 8,876,346 View
May 15, 2026 SCHEDULE 13G/A Julian C. Baker 9.99% 8,876,346 View
May 15, 2026 SCHEDULE 13G/A Felix J. Baker 9.99% 8,876,346 View
May 15, 2026 SCHEDULE 13G/A BIOTECHNOLOGY VALUE FUND L P 3.4% 2,716,569 View
May 15, 2026 SCHEDULE 13G/A BVF I GP LLC 3.4% 2,716,569 View
May 15, 2026 SCHEDULE 13G/A BIOTECHNOLOGY VALUE FUND II LP 2.5% 1,986,984 View
May 15, 2026 SCHEDULE 13G/A BVF II GP LLC 2.5% 1,986,984 View
May 15, 2026 SCHEDULE 13G/A Biotechnology Value Trading Fund OS LP 0.4% 306,361 View
May 15, 2026 SCHEDULE 13G/A BVF Partners OS Ltd. 0.4% 306,361 View
May 15, 2026 SCHEDULE 13G/A BVF GP HOLDINGS LLC 5.8% 4,703,553 View
May 15, 2026 SCHEDULE 13G/A BVF PARTNERS L P/IL 6.3% 5,085,886 View
May 15, 2026 SCHEDULE 13G/A BVF INC/IL 6.3% 5,085,886 View
May 15, 2026 SCHEDULE 13G/A LAMPERT MARK N 6.3% 5,085,886 View
Apr 22, 2026 SCHEDULE 13G/A Adam Goulburn 8.1% 6,513,765 View
Apr 22, 2026 SCHEDULE 13G/A Zavain Dar 8.1% 6,513,765 View
Apr 22, 2026 SCHEDULE 13G/A Nan Li 8.1% 6,513,765 View
Apr 22, 2026 SCHEDULE 13G/A Dimension Management, L.P. 8.1% 6,513,765 View
Apr 22, 2026 SCHEDULE 13G/A Dimension Capital I GP, LLC 7.1% 5,663,265 View
Apr 22, 2026 SCHEDULE 13G/A Dimension Management GP, LLC 8.1% 6,513,765 View
Apr 22, 2026 SCHEDULE 13G/A Dimension Capital I, L.P. 7.1% 5,663,265 View
Apr 22, 2026 SCHEDULE 13G/A Dimension Capital II, L.P. 1.1% 850,500 View
Apr 22, 2026 SCHEDULE 13G/A Dimension Capital II GP, LLC 1.1% 850,500 View
Mar 19, 2026 SCHEDULE 13D/A — 1.0% — View
Feb 17, 2026 SCHEDULE 13G/A BIOTECHNOLOGY VALUE FUND L P 3.1% 2,050,405 View
Feb 17, 2026 SCHEDULE 13G/A BVF I GP LLC 3.1% 2,050,405 View
Feb 17, 2026 SCHEDULE 13G/A BIOTECHNOLOGY VALUE FUND II LP 2.3% 1,496,859 View
Feb 17, 2026 SCHEDULE 13G/A BVF II GP LLC 2.3% 1,496,859 View
Feb 17, 2026 SCHEDULE 13G/A Biotechnology Value Trading Fund OS LP 0.4% 232,097 View
Feb 17, 2026 SCHEDULE 13G/A BVF Partners OS Ltd. 0.4% 232,097 View
Feb 17, 2026 SCHEDULE 13G/A BVF GP HOLDINGS LLC 5.4% 3,547,264 View
Feb 17, 2026 SCHEDULE 13G/A BVF PARTNERS L P/IL 5.9% 3,835,886 View
Feb 17, 2026 SCHEDULE 13G/A BVF INC/IL 5.9% 3,835,886 View
Feb 17, 2026 SCHEDULE 13G/A LAMPERT MARK N 5.9% 3,835,886 View
Feb 17, 2026 SCHEDULE 13G/A Baker Bros. Advisors LP 6.7% 4,345,736 View
Feb 17, 2026 SCHEDULE 13G/A Baker Bros. Advisors (GP) LLC 6.7% 4,345,736 View
Feb 17, 2026 SCHEDULE 13G/A Julian C. Baker 6.7% 4,345,736 View
Feb 17, 2026 SCHEDULE 13G/A Felix J. Baker 6.7% 4,345,736 View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.